PROFHILO H+L (1x2ml) IBSA

PROFHILO (IBSA Derma): The Revolution in Injectable Bioremodeling

The Objective of Profhilo:

Unlike traditional fillers (such as ALIAXIN) that add volume, Profhilo is designed to bioremodel the extracellular matrix and stimulate tissues. It aims to improve the elasticity, firmness, and overall quality of sagging skin.

Profhilo: The Hybrid Cohesive Complex (HCC) and NAHYCO™

This is the first stabilized hyaluronic acid (HA) product manufactured without the use of chemical crosslinking agents (BDDE). Profhilo's uniqueness lies in its formulation: it is the first injectable stabilized HA without chemical crosslinking agents (such as BDDE).

• NAHYCO™ Technology: Profhilo is thermally stabilized, creating a patented Hybrid Cohesive Complex (HCC) composed of 100% Hyaluronic Acid.
• High Molecular Weight HA: Provides structure and long-lasting hydration.
• HA of Low Molecular Weight: Hydrates the deep layer of the dermis and stimulates the production of endogenous hyaluronic acid (HA).
• High Concentration: Profhilo has one of the highest concentrations of HA on the market (64 mg/2 ml) without excessive volumizing effect.
• Tissue Diffusion: Its low viscosity allows it to diffuse widely into the tissues (flooding effect) from a limited number of injection points.
• MEDICAL DEVICE. Use of this product is exclusively reserved for a licensed physician. Important: This product is intended for use only by qualified and authorized personnel trained in the administration of injections. Class III medical device with CE marking.

PRESENTATION

• Pre-filled 2 ml syringe.
• 2 TERUMO needles, type 29G x 1/2 (29G x 13).
• Product information leaflet.
• 2 self-adhesive product traceability labels.

INDICATIONS

The specific injection protocol for Profhilo is the BAP (Bio Aesthetic Points) Protocol, designed to maximize product diffusion in the critical anatomical areas of the face, neck, and body associated with aging.

• Main Indication: Skin laxity (sagging), deep dehydration, loss of firmness and firmness.
• Treatment Areas: Face, neck, décolleté, and specific body areas (arms, hands, abdomen).
• Efficacy: Profhilo acts on all three types of dermal cells (keratinocytes, fibroblasts, and adipocytes), restoring tissue architecture and function.
• The injectable medical device PROFHILO intervenes in the physiological processes of skin aging and in the repair of dermal tissue in cases of scarring resulting from superficial skin trauma.
• PROFHILO is used for skin remodeling and the treatment of skin laxity, not just for fillers and wrinkles.
• With one of the highest concentrations of HA on the market (64 mg/2 ml), it not only stimulates and hydrates the skin but also remodels aging tissue and Sagging.

PROFILE DETAILS

• TREATMENT OBJECTIVE / INDICATION: BIOREMODEL FOR SKIN LAXITY.
• AREA: FACE, NECK, DÉCOLLETÉ.
• HA CONCENTRATION: 64 MG PER 2 ML.
• HYDRO ACTION: 5/5
• LIFT ACTION: 3/5
• PACKAGING: 1 PRE-FILLED 2 mL SYRINGE.
• NECK: 29G THIN WALLS x 13 mm.
• PROTOCOL: 2 SESSIONS. Evaluation 2 months after the last treatment. Repeat the treatment if necessary.
• PROPOSED TECHNIQUE: BAP.
• INJECTION LAYER: DEEP DERMIS.
• STRICTLY FOR MEDICAL USE IN A MEDICAL OFFICE.

COMPOSITION

Stable hybrid cooperative complexes of low and high molecular weight hyaluronic acid. 

• 3.2% – 32 mg (H-HA) + 32 mg (L-HA)/2 ml Hyaluronic acid sodium salt.
• 3.2% – 16 mg (H-HA) + 16 mg (L-HA)/1 ml Hyaluronic acid sodium salt.

Medical device for intradermal use. Sterile. Single use only.

INJECTION AREAS

• PROFHILO is indicated for facial and body treatments to redefine contours and correct laxity.
• However, it is particularly indicated for treating the malar-zygomatic, submalar, brachial, and abdominal areas, as well as areas affected by skin laxity.

DURABILITY

As a stabilized product, Profhilo lasts in the skin for approximately 28 days.

RESULTS

• Improved tissue quality.
• Skin remodeling.
• Treatment of skin laxity.
• Restoration of

Skin firmness.

IBSA Derma: Swiss Innovation at the Heart of Hyaluronic Acid

IBSA Derma (the aesthetic division of IBSA Institut Biochimique SA, Switzerland) is a pharmaceutical leader recognized for its expertise in the production of ultra-high-purity Hyaluronic Acid (HA), manufactured in its certified plant in Italy. PROFHILO is a unique product from IBSA, which has created a new category in aesthetics: Bioremodeling.

IBSA's hyaluronic acid is ultrapure, produced by a patented bio-fermentation process of Streptococcus Zooepidemicus, classified worldwide as "superior quality" in terms of purity, safety, and high resistance to thermal production processes.

The formulation of HA with varying molecular weights contained in PROFHILO is based on a Hydrolift Action concept. This innovative approach aims to counteract the physiological reduction of hyaluronic acid (HA) in the skin, restoring hydration, elasticity, and tone by synergistically combining deep hydration with the mechanical action of skin lifting.

IBSA Italia

PROFHILO is manufactured by IBSA Farmaceutici Italia at an FDA-approved facility in Italy and distributed in the UK and Ireland by HA-Derma Ltd.